For research use only. Not for therapeutic Use.
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research[1].
| Catalog Number | I044198 |
| CAS Number | 2296814-85-0 |
| Molecular Formula | C192H302N46O57 |
| Purity | ≥95% |
| Reference | [1]. Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome. 26 June 2019. |
